CD274 and hepatocellular carcinoma: Post-LT HCC patients face multiple clinical challenges, including the lack of reliable biomarkers to predict ICI efficacy, with existing markers (e.g., PD-L1 expression, TMB) showing limited applicability under complex immunosuppressive conditions.